Related Experiment Video

Updated: Jan 27, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

740

Evaluation of drug combination effect using a Bliss independence dose-response surface model

Qin Liu1, Xiangfan Yin1, Lucia R Languino2

  • 1Molecular and Cellular Oncogenesis Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104.

Statistics in Biopharmaceutical Research
|March 19, 2019
PubMed

Insights

This study introduces a new statistical model for evaluating drug combinations, improving upon traditional methods for anticancer drug screening. The model provides a robust interaction index for determining synergistic effects, accelerating preclinical research.

Area of Science:

  • Pharmacology
  • Biostatistics
  • Oncology

Background:

  • Traditional methods for assessing drug synergy, like heat maps, are inefficient and lack statistical rigor for drug screening.
  • Evaluating anticancer drug combinations requires statistically robust methods to determine synergistic effects accurately.

Purpose of the Study:

  • To develop and validate a statistically rigorous two-stage Bliss independence response surface model for estimating drug combination interaction.
  • To provide a reliable method for determining overall synergistic effects of drug combinations using an interaction index (τ) with a 95% confidence interval (CI).

Main Methods:

  • A two-stage Bliss independence response surface model was developed to estimate an overall interaction index (τ).
  • The model incorporates all data points to provide a statistically robust assessment of drug combination effects.
  • The proposed model was compared with classic Bliss independence models using example data.

Main Results:

  • The two-stage model provides a statistically rigorous estimation of the overall interaction index (τ) with a 95% CI.
  • Data analysis using the new model showed comparable patterns to classic Bliss rule models.
  • The overall τ with 95% CI enables a clear determination of synergistic drug combination effects.

Conclusions:

  • The developed two-stage model offers a statistically sound and robust approach for evaluating drug combination synergy.
  • This method enhances decision-making in preclinical drug screening by providing a reliable interaction index.
  • The model accelerates the drug screening process, aiding in the identification of effective anticancer drug combinations.
Keywords:
Bliss independencedrug combinationinteraction indexsynergistic effect

More Related Videos

Microinjectrode System for Combined Drug Infusion and Electrophysiology08:30

Microinjectrode System for Combined Drug Infusion and Electrophysiology

Published on: November 13, 2019

7.3K
Preparation of Light-responsive Membranes by a Combined Surface Grafting and Postmodification Process12:00

Preparation of Light-responsive Membranes by a Combined Surface Grafting and Postmodification Process

Published on: March 21, 2014

12.2K

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.0K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
277
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
242
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
216
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.5K